Experience with enfuvirtide (fuzeon) in the treatment regimens for HIV infection


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The authors describe their experience with enfuvirtide (fuzeon) used in the inhospital treatment of HIV-infected comatous patients with a low (less than 50 cells/pl) CD4 lymphocyte count, who are unable to use medicinal tablets. For rescue therapy, patients were given antiretroviral agents as liquid formulations through a tube and subcutaneous enfuvirtide. The authors’ experience verifies that it is advisable to use enfuvirtide in combination with other antiretroviral agents: 1) in central nervous system dysfunction and inability to take medicinal tablets; 2) when administered as part of first-line antiretroviral therapy if there is a considerable immunosuppression (the count of CD4 lymphocytes is less than 50-100 cells/pl) and progression of life-threatening opportunistic infections (including tuberculosis); 3) as an induction regimen over 12-24 weeks.

Full Text

Restricted Access

About the authors

E. V Beketova

Center for AIDS Prevention and Control

Email: rostaids@aaanet.ru
Rostov-on-Don

S. A Bykov

Center for AIDS Prevention and Control

Email: bykov_s_a_63@mail.ru
Rostov-on-Don

References

  1. Eggink D., Berkhout B., Sanders R.W. Inhibition of HIV-1 by fusion inhibitors. Curr. Pharm. Des. 2010; 16(33): 3716-3728.
  2. Bonora S., Calcagno A., Cometto C. et al. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. Infection 2012; 40(1): 69-75.
  3. Joly V., Jidar K., Tatay M., Yeni P. Enfuvirtide: from basic investigations to current clinical use. Ехреrt Оріп. Pharmacother. 2010; 11(16): 2701-2713.
  4. Makinson A., Reynes J. The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr. Оріп. HIV AIDS 2009; 4(2): 150-158.
  5. Кравченко А.В., Канестри В.Г. Применение ингибитора слияния энфувиртида в схемах антиретровирусной терапии у больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2013; 1: 47-52.
  6. Cooper D., Gatell J., Rockstroh J. et al. and the BENCHMRK-1 Study Group. 48-week results from BENCHMRK-1, a phase III study of raltegravir in patients failing ART with tripleclass resistant HIV-1. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008. Boston, Mass. Abstract 788.
  7. Cahn P., Molina J.-M., Towner W., Peeters M., Vingerhoets J., Beets G. et al. 48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virological response to etravirine (TMC125; ETR). In: 17th International AIDS Conference. 3-8 August 2008. Mexico City. Abstract TUPE0047.
  8. Lalezari J., Goodrich J., DeJesus E. et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. In: 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007. Los Angeles, California. Аbstract 104bLB.
  9. Мазус А.И., Каминский Г.Д., Зимина В.Н., Бессараб Т.П., Пронин А.Ю., Цыганова Е.В. и др. Национальные клинические рекомендации по диагностике и лечению ВИЧ-инфекции у взрослых. М., 2013.
  10. Шахгильдян В.И., Беляева В.В. Паллиативная помощь при ВИЧ/СПИДе. Руководство по оказанию паллиативной помощи людям, живущим с ВИЧ. М., 2007. 170 с.
  11. Ермак Т.Н., Кравченко А.В., Груздев Б.М. Вторичные заболевания у больных ВИЧ-инфекцией - 15-летнее наблюдение. Тер. архив 2004; 76: 18-20.
  12. Johnson M., Sabin C., Girardi E. Definition and epidemiology of late presentation in Europe. Antivir. Ther. 2010; 15(Suppl. 1): 3-8.
  13. When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-1363.
  14. Сборник статей науч-практ. конф. «Достижение региональной стратегии по обеспечению универсального доступа к профилактике, диагностике и лечению ВИЧ-инфекции в Ростовской области». Ростов-на-Дону, 2009.
  15. Кравченко А.В., Кузнецова А.В. Козырев О.А., Лукьянова В.А., Канестри В.Г., Зимина В.Н Ингибитор слияния энфувиртид в схемах АРВТ у больных с ВИЧ-инфекцией и туберкулезом. ВИЧ-инфекция и иммуносупрессии 2010; 2(4): 35-41.
  16. Lalezari J.P., Henry K., O’Hearn М., Montaner J.S.G., Piliero P.J., Trottier B. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 2003; 348: 2175-2185.
  17. Lazzarin A., Clotet B., Cooper D., Reynes J., Arastéh K., Nelson M. et al.; TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 2003; 348: 2186-2195.
  18. Bartlett J., Salgo M., DeMasi R. Early viral load responses on enfuvirtide in heavily treatment-experienced patients. Program and abstracts of the 15th International AIDS Conference. July 11-16 2004. Bangkok, Thailand. Abstract TuPeB4484.
  19. Clotet B., Bellos N., Molina J.M., Cooper D., Goffard J.C., Lazzarin A. et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369(9568): 1169-1178.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media